Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Myeloproliferative Disorders 9Primary Myelofibrosis 8Pancreatic Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Myeloid, Acute 4Leukemia 4Breast Neoplasms 4Prostatic Neoplasms 3Myelodysplastic Syndromes 3Multiple Myeloma 3Thrombocythemia, Essential 2Lymphoma, Non-Hodgkin 2Lymphoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hematologic Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Thrombocytosis 1Squamous Cell Carcinoma of Head and Neck 1Polycythemia Vera 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Myelodysplastic-Myeloproliferative Diseases 1Lymphoproliferative Disorders 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1

Interventions

ruxolitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Cancer Cachexia × ruxolitinib × Clear all
NCT02072057 2019-02-28

Study of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.

Kantonsspital Aarau

Phase 2 Terminated
8 enrolled

Cancer Cachexia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡